Výsledky vyhledávání - "Mary Clare Walker"

Akademický článek

The Potential of Vaccines for the Control of AIDS

Autor: Margaret I Johnston, Patricia E Fast, Mary Clare Walker, Daniel Hoth

Publikováno v: Canadian Journal of Infectious Diseases, Vol 5, Iss Suppl A, Pp 36A-41A (1994)

The goal of a prophylactic human immunodeficiency (HIV) vaccine is to elicit immune response(s) that will, upon subsequent exposure to HIV. prevent lnfection and/or disease. On the other hand. therapeutic administration of a vaccine to an individual

Externí odkaz: https://doaj.org/article/20dcb6834019413da8c4b6ef1195a3e8

Zobrazit plný text záznamu

A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8+Cytotoxic T Lymphocyte Responses in Seronegative Volunteers

Autor: Mark J. Mulligan, Kent J. Weinhold, Barney S. Graham, Patricia E. Fast, David C. Montefiori, Jean-Louis Excler, Geoffrey J. Gorse, M. Juliana McElrath, Ann-Marie Duliege, Michael C. Keefer, Mary Clare Walker, Mary Lou Clements-Mann, James Tartaglia, Mark Wolff, Thomas G. Evans

Publikováno v: The Journal of Infectious Diseases. 180:290-298

Induction of CD8 + cytotoxic T cells is considered one of the important correlates for the protective efficacy of candidate human immunodeficiency virus type 1 (HIV-1) vaccines. To induce CD8 + cytotoxic T lymphocytes (CTLs) along with neutralizing a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8d7c25c58474b861a084dadef7ca06c
https://doi.org/10.1086/314895

Zobrazit plný text záznamu

HIV-1MN Recombinant Glycoprotein 160 Vaccine-Induced Cellular and Humoral Immunity Boosted by HIV-1MN Recombinant Glycoprotein 120 Vaccine

Autor: Robert B. Belshe, T J Matthews, Martha M. Eibl, Lawrence Corey, M J McElrath, R H Hsieh, Mahendra Mandava, Geoffrey J. Gorse, Gira B. Patel, Mary Clare Walker, Phillip W. Berman

Publikováno v: AIDS Research and Human Retroviruses. 15:115-132

We evaluated prime-boost immunization with two recombinant envelope glycoprotein subunit vaccines (HIV-1MN recombinant gp160 vaccine in alum adjuvant [MN rgp160] and HIV-1MN recombinant gp120 vaccine in alum adjuvant [MN rgp120]) for safety and immun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2428eabcc62c7bb7271e46e05c11c45
https://doi.org/10.1089/088922299311547

Zobrazit plný text záznamu

Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group

Autor: Raphael P. Viscidi, Marcy Winget, David H. Schwartz, Mark Wolff, Barbara Clayman, John S. Lambert, Mary Clare Walker

Publikováno v: Clinical Diagnostic Laboratory Immunology. 4:302-308

Twenty-two human immunodeficiency virus type 1 (HIV-1)-infected, asymptomatic volunteers with CD4 cell counts of >600 cells/mm3 who were enrolled in a phase I immunotherapy trial comparing two schedules of immunization of an HIV-1 IIIB-based recombin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfabc2b9549e71d9d690b9659fd2a8dc
https://doi.org/10.1128/cdli.4.3.302-308.1997

Zobrazit plný text záznamu

Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type 1

Autor: Raphael Dolin, M L Clements, John R. Mascola, Francine E. McCutchan, Barney S. Graham, M J McElrath, Mary Clare Walker, Michael C. Keefer, Geoffrey J. Gorse, John G. McNeil, Owen S. Weislow, David H. Schwartz, Donald S. Burke, R B Belshe, S M Belay, S W Snyder, Kenneth F. Wagner

Publikováno v: Journal of Infectious Diseases. 173:340-348

Phase I studies of volunteers not infected with human immunodeficiency virus type 1 (HIV-1) have shown that immunization with envelope subunit vaccine products elicits antibodies that neutralize laboratory-adapted (prototype) HIV-1 strains in vitro.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::14c941d08575cd9629844bb3d1c50cc2
https://doi.org/10.1093/infdis/173.2.340

Zobrazit plný text záznamu

Summary Report: Workshop on the Potential Risks of Antibody-Dependent Enhancement in Human HIV Vaccine Trials

Autor: Mary Clare Walker, Scott B. Halstead, John R. Mascola, Bonnie J. Mathieson, Philip M. Zack, Donald S. Burke

Publikováno v: AIDS Research and Human Retroviruses. 9:1175-1184

Concern that ADE of HIV infection could occur in vivo, as a result of HIV immunization, has arisen for several reasons. Immune-mediated disease enhancement occurs in several human and animal viral diseases, including lentiviral diseases. Tropism for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c5ccdeaaa7bd7f826ec1e5dd23a2da47
https://doi.org/10.1089/aid.1993.9.1175

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání